Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

PHASE2UnknownINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

June 30, 2019

Conditions
Breast Cancer
Interventions
DRUG

Trastuzumab

"\- Eight times IV administration of trastuzumab per 3 weeks~* Trastuzumab 8mg/kg on Day 1 of Cycle 1~* Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"

DRUG

Letrozole

\- Daily letrozole 2.5 mg/day for 24 weeks

Trial Locations (14)

135720

RECRUITING

Gangnam Severance Hospital, Seoul

Unknown

RECRUITING

Hallym University Sacred Heart Hospital, Anyang

NOT_YET_RECRUITING

Inje University Pusan Paik Hospital, Busan

RECRUITING

Dankook University Hospital, Cheonan

RECRUITING

Ilsan Paik Hospital, Goyang

NOT_YET_RECRUITING

National Cancer Center, Goyang

NOT_YET_RECRUITING

Asan Medical Center, Seoul

RECRUITING

Kangbuk Samsung Hospital, Seoul

RECRUITING

Korea Institute of Radiological and Medical Sciences, Seoul

RECRUITING

Korea University Anam Hospital, Seoul

NOT_YET_RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Ajou University School of Medicine, Suwon

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

collaborator

Severance Hospital

OTHER

collaborator

Samsung Medical Center

OTHER

collaborator

Asan Medical Center

OTHER

lead

Gangnam Severance Hospital

OTHER